NCT02492711Phase 3Completed

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Study sponsor: MacroGenics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-08-11Actual
Enrollment · participants624Actual
Source updated2025-03-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.